Loading
Breast Cancer Treatment Studies / HER2/EGFR in Cancer Research / Advanced Breast Cancer Therapies · Journal article
Frontiers in Oncology · September 7, 2026
Reinforces what was already believed, rather than introducing something new.
This retrospective cohort of 107 Vietnamese patients treated with first-line CDK4/6 inhibitors (ribociclib or palbociclib) plus endocrine therapy for HR+/HER2− metastatic breast cancer reports a median PFS of 28.0 months and 24-month OS rate of 87.8%, outcomes concordant with pivotal randomized trials. The study confirms efficacy and tolerability in a real-world Asian population but lacks randomization, a comparator arm, and mature OS data, limiting its ability to establish new practice standards.
Retrospective cohort study, single center, non-randomized. 107 patients with HR-positive, HER2-negative metastatic breast cancer treated at Ho Chi Minh City Oncology Hospital.. Intervention: First-line ribociclib or palbociclib in combination with an aromatase inhibitor or fulvestrant. n = 107. Ho Chi Minh City Oncology Hospital, Vietnam.
Median PFS was 28.0 months with 12-month and 24-month PFS rates of 66.4% (95% CI, 56.6%–74.4%) and 54.1% (95% CI, 44.2%–63.0%) Median OS not reached; 12-month and 24-month OS rates were 88.8% and 87.8% respectively Grade 3–4 neutropenia observed in 58.8% of patients; no febrile neutropenia cases documented
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
This real-world data supports the efficacy and tolerability of first-line CDK4/6 inhibitors with endocrine therapy in Vietnamese patients with HR+/HER2− metastatic breast cancer, broadly confirming established trial results. Clinicians should interpret these findings as consistent with rather than additive to pivotal trial evidence, with neutropenia management by dose modification validated in this population.
Retrospective single-center cohort confirming that CDK4/6 inhibitors with endocrine therapy produce PFS and OS outcomes consistent with pivotal trials in HR+/HER2− metastatic breast cancer, but lacks the design rigor and sample size for practice guidance beyond established use.
As stated by the source record.
Quoted from the source exactly as published.
This real-world data supports the efficacy and tolerability of first-line CDK4/6 inhibitors with endocrine therapy in Vietnamese patients with HR+/HER2− metastatic breast cancer, broadly confirming established trial results. Clinicians should interpret these findings as consistent with rather than additive to pivotal trial evidence, with neutropenia management by dose modification validated in this population.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
Objective This study aimed to characterize the tumor response rate, progression-free survival (PFS), and overall survival (OS) among patients with HR-positive, HER2-negative metastatic breast cancer receiving CDK4/6 inhibitors plus endocrine therapy at Ho Chi Minh City Oncology Hospital. Secondary objectives included identifying clinical factors associated with survival outcomes and characterizing treatment-related toxicities. Materials and methods We conducted a retrospective cohort study enrolling 107 patients who received first-line ribociclib or palbociclib in combination with an aromatase inhibitor or fulvestrant at Ho Chi Minh City Oncology Hospital between March 1, 2021, and April 1, 2023. Results The median follow-up duration was 29 months. The median PFS was 28.0 months. The Kaplan–Meier-estimated PFS rates at 12 and 24 months were 66.4% (95% CI, 56.6%–74.4%) and 54.1% (95% CI, 44.2%–63.0%), respectively. The median OS was not reached; corresponding OS rates at 12 and 24 months were 88.8% and 87.8%, respectively. On multivariate Cox regression analysis, ER and PR expression levels emerged as independent prognostic determinants of PFS. Grade 3–4 neutropenia was observed in 58.8% of patients; all events were managed through dose interruption or reduction, and no cases of febrile neutropenia were documented. Conclusion CDK4/6 inhibitors (ribociclib or palbociclib) combined with endocrine therapy demonstrated favorable efficacy and tolerability in Vietnamese patients with HR-positive, HER2-negative metastatic breast cancer. Treatment outcomes and safety profiles were consistent with those reported in pivotal clinical trials and real-world studies. These findings should be interpreted in light of the retrospective single-center design, modest sample size, non-randomized treatment allocation, and immature OS data.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.